ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER).

How it works

Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.

What the body does with it

Metabolism	Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Excretion	Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Half-life	Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Protein binding	Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Volume of Distribution	Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within seconds to minutes) for correction of fluid and electrolyte imbalances.
Duration of Action	Dependent on infusion rate and patient's metabolic state; effects persist as long as infusion continues. Cessation results in rapid return to baseline within 1-2 hours for dextrose, with electrolyte effects lasting up to several hours.

Classification & Brands

Dosing & administration

Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 mL/hour, up to 2-3 L/day.

Dosage form	INJECTABLE
Renal impairment	Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Liver impairment	No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Pediatric use	Weight-based: 100-150 mL/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Geriatric use	Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER).

Breastfeeding	Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Teratogenic Risk	No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.

Warnings & precautions

■ FDA Black Box Warning

NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.

Clinical Precautions

Precautions

Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Excretion	Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Half-life	Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Protein binding	Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Volume of Distribution	Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: immediate (within seconds to minutes) for correction of fluid and electrolyte imbalances.
Duration of Action	Dependent on infusion rate and patient's metabolic state; effects persist as long as infusion continues. Cessation results in rapid return to baseline within 1-2 hours for dextrose, with electrolyte effects lasting up to several hours.

Classification & Brands

Dosing & administration

Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 mL/hour, up to 2-3 L/day.

Dosage form	INJECTABLE
Renal impairment	Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Liver impairment	No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Pediatric use	Weight-based: 100-150 mL/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Geriatric use	Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER (ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER).

Breastfeeding	Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Teratogenic Risk	No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.